-transparent.png){kind=logo}
A non-ionic water-soluble contrast medium, Amipaque (metrizamide), was studied for use in ventriculography both experimentally and clinically, and identified as having markedly low toxicity. Twenty adult mongrel dogs were injected intraventricularly of intracisternally with 2.0 to 5.0 ml of Amipaque. It was found that Amipaque is safe compared with other water-soluble contrast media, especially relative to epileptogenic effect. The authors also carried out 17 clinical trials of ventriculography using 4.0 to 15.0 ml of Amipaque in 13 neurosurgical patients. There were no troublesome symptoms except for a mild headache as a side-effect in one patient, and Amipaque proved to be a satisfactory diagnostic contrast medium.
S Suzuki, and
K Ito, and
T Iwabuchi
August 1979,
Journal of neurosurgery,
S Suzuki, and
K Ito, and
T Iwabuchi
January 1979,
Dento maxillo facial radiology,
S Suzuki, and
K Ito, and
T Iwabuchi
May 1976,
Nederlands tijdschrift voor geneeskunde,
S Suzuki, and
K Ito, and
T Iwabuchi
September 1975,
Acta radiologica: diagnosis,
S Suzuki, and
K Ito, and
T Iwabuchi
January 1976,
Acta radiologica. Supplementum,
S Suzuki, and
K Ito, and
T Iwabuchi
July 1975,
Radiology,
S Suzuki, and
K Ito, and
T Iwabuchi
March 1975,
Acta radiologica: diagnosis,
S Suzuki, and
K Ito, and
T Iwabuchi
February 1981,
The Medical journal of Australia,
S Suzuki, and
K Ito, and
T Iwabuchi
November 1978,
Ceskoslovenska neurologie a neurochirurgie,
S Suzuki, and
K Ito, and
T Iwabuchi
February 1976,
Ugeskrift for laeger,
